The GUSTO trial (NCT03745586) investigated the efficacy and safety of tocilizumab (TCZ )-monotherapy after ultra-short glucocorticoid treatment in new-onset giant cell arteritis (GCA). touchIMMUNOLOGY caught up with Dr. Lisa Christ (University of Bern, Inselspital, Bern, Switzerland) to discuss this analysis of GUSTO exploring the maintenance of remission 1 year after discontinuation of TCZ treatment.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial.’ (Abstract number: 0470) was presented at the ACR Convergence, November 10–14, 2022.
- What is known about the efficacy and safety of tocilizumab in the treatment of giant cell arteritis (GCA)? (0:16)
- Could you give us a brief overview of the GUSTO trial and its findings? (1:08)
- What were the objectives of the current analysis of the GUSTO trial? (2:12)
- What were the findings of this analysis? (2:41)
- Why was the relapse rate lower than those reported in earlier clinical trials? (3:12)
Disclosures: Lisa Christ discloses receiving grant/ research support from F. Hoffmann-La Roche, Gilead Sciences, and Pfizer; serving on advisory boards for Bristol-Myers Squibb and Novartis; and other financial support from F. Hoffmann-La Roche, Bristol-Myers Squibb, and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Atiya Henry
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Rheumatic Diseases
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Catherine Sims, ACR 2022: Azathioprine metabolite levels throughout pregnancy in women with rheumatic disease
Women with rheumatic disease, such as systemic lupus erythematosus, are often prescribed azathioprine to control disease activity during pregnancy. However, the changes in azathioprine metabolite levels throughout pregnancy in such women are yet to be well-characterized. It was a pleasure to talk with Dr. Catherine Sims (Duke University, Durham, NC, USA) around her study investigating […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!